Development and Validation of Serum Markers as Noninvasive Diagnostic Methods for Achalasia
Open Access
- 3 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 15 (1) , e00651
Abstract
INTRODUCTION: Currently, the diagnosis of achalasia mainly relies on invasive or radioactive examinations. This study aimed to develop a noninvasive diagnostic method for achalasia based on specific serum markers. METHODS: Serum levels of profilin-1, galectin-10, immunoglobulin heavy variable 3–9, vasodilator-stimulated phosphoprotein, and transgelin-2 were measured in patients with achalasia and controls by enzyme-linked immunosorbent assay. The diagnostic values and thresholds were determined by the receiver operating characteristic curve analysis. Then, patients with dysphagia were prospectively enrolled to validate the ability of these molecules for achalasia diagnosing. RESULTS: A total of 142 patients with achalasia and 50 nonachalasia controls (healthy volunteers and patients with reflux esophagitis) were retrospectively included. The serum levels of profilin-1, galectin-10, and transgelin-2 in patients with achalasia were significantly higher than those in healthy volunteers and patients with reflux esophagitis (P all < 0.001). Profilin-1, galectin-10, and transgelin-2 were of good performance in diagnosing achalasia, with optimal thresholds of 2,171.2, 33.9, and 1,630.6 pg/mL, respectively. Second, 40 patients with dysphagia were prospectively enrolled to the validation of achalasia. For profilin-1, the positive predictive value, negative predictive value, sensitivity, and specificity were 100.0%, 64.5%, 45.0%, and 100.0%, respectively. The figures for transgelin-2 were 65.5%, 90.9%, 95.0%, and 50.0%. When both increased, the positive predictive value reached to 100.0%. When both indexes were normal, the negative predictive value was 100.0%. DISCUSSION: Profilin-1 and transgelin-2 were promising biomarkers for achalasia diagnosis and performed better in combination. Further multicenter studies are necessary to verify their application as preliminary screening tools for achalasia.Keywords
Funding Information
- Innovative Research Group Project of the National Natural Science Foundation of China (82170577)
- Innovative Research Group Project of the National Natural Science Foundation of China (81970479)
- Natural Science Foundation of Guangdong Province (2023A1515010187)
- Provincial and municipal joint Fund Youth Project of Guangdong (2022A1515111159)
This publication has 41 references indexed in Scilit:
- The tumor‐suppressive function of miR‐1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinomaJournal of Gastroenterology and Hepatology, 2016
- Uses of Esophageal Function TestingGastrointestinal Endoscopy Clinics of North America, 2014
- Proteomic Identification of Proteins Suggestive of Immune-Mediated Response or Neuronal Degeneration in Serum of Achalasia PatientsGut and Liver, 2013
- Erroneous Diagnosis of Gastroesophageal Reflux Disease in AchalasiaClinical Gastroenterology and Hepatology, 2011
- Proteomics of Smad4 regulated transforming growth factor-beta signalling in colon cancer cellsMolecular BioSystems, 2010
- The Cost of Achalasia: Quantifying the Effect of Symptomatic Disease on Patient Cost Burden, Treatment Time, and Work ProductivitySurgical Innovation, 2010
- Peroral endoscopic myotomy (POEM) for esophageal achalasiaEndoscopy, 2010
- Structure and functions of profilinsBiophysical Reviews, 2009
- Profilin, a multi‐modal regulator of neuronal plasticityBioEssays, 2008
- The Ena/VASP enigmaJournal of Cell Science, 2002